About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Cannabinoid Therapy for Pediatric Epilepsy | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT02983695

Cannabinoid Therapy for Pediatric Epilepsy

This is a Phase 1 trial to determine the tolerability and optimal dose of CBD rich cannabis extract as an adjunct treatment in children with severe drug resistant epilepsy due to Dravet Syndrome. This...

Lead sponsor: The Hospital for Sick Children•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

The Hospital for Sick Children

Collaborators

Tilray

Age

1 - 18 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Drug resistant epilepsy due to Dravet syndrome
•Must have clinically apparent seizures
•Must be able to tolerate administration of medication orally or enterally via gastrostomy tube
•Was never on Cannabinoid therapy or have not been treated with Cannabinoid products for at least last 60 days (confirmed by negative urine test for Tetrahydrocannabidiol (THC), only for those who had been treated with CBD).

Exclusion Criteria

•Co-morbid liver or renal disease
•Without clinically-apparent seizures
•Currently taking any Cannabinoid products.

Related studies

RECRUITINGPhase 1

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880 · Epilepsy

The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy

NCT06097195 · Epilepsy

RECRUITINGPhase 3

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT06315322 · Childhood Absence Epilepsy, Juvenile Absence Epilepsy

RECRUITINGPhase 1/2

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707 · Drug Resistant Epilepsy, Epilepsy, and more

RECRUITINGPhase 3

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

NCT07505004 · Focal Epilepsy

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 16, 2021Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment20

Start dateFeb 2017

Last updatedNov 16, 2021

Condition

Locations shown

The Hospital for Sick Children

Toronto, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 16, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions